DMPK and Bioanalytical Strategies for the Successful Development of Antibody-Drug Conjugates (ADCs)
ADCs combine the targeting capabilities of antibodies with the potent cytotoxic effects of small molecule drugs. This dual nature necessitates specific strategies for the discovery and development of ADCs, paving the way for accelerated clinical development.
This webinar discusses:
- DMPK considerations during discovery and early development
- Bioanalytical strategies to measure ADCs
- Immunogenicity considerations
- PK/PD modeling and simulations
Moderated by: Robert MacNeill – Director, Bioanalysis at Pharmaron
SpeakersVaishali Dixit – Head of DMPK at Mersana Therapeutics
Dr. Vaishali Dixit is currently Head of DMPK at Mersana Therapeutics. She holds a PhD in Medicinal Chemistry from the University of Florida and has conducted postdoctoral work at the University of Washington. She has over 15 years of experience in drug discovery and development and has contributed to several regulatory submissions. She has worked in multiple modalities including small molecules, ADCs, and protein degraders, spanning programs from early discovery into early development. She has participated in industry consortia on PBPK models for DDI and Special Populations resulting in peer reviewed publications. Prior to joining Mersana, Vaishali has held roles of increasing responsibilities at Vertex, Eisai and Kymera Therapeutics.
Rafiq Islam – Executive Director of CGT and Biologics Bioanalysis at Pharmaron
Rafiq Islam is the Executive Director of CGT and Biologics Bioanalysis at Pharmaron, where he drives both scientific innovation and operational excellence within the CGT (Cell and Gene Therapy) and Biologics Bioanalytical division. His leadership is distinguished by a focus on groundbreaking solutions in bioanalysis, where he tackles complex challenges with innovative approaches. With over 25 years of industry experience, Rafiq has been at the forefront of bioanalytical innovation, holding key leadership positions at top CROs such as Labcorp, Celerion, and Amador Biosciences. His strategic vision has not only advanced bioanalytical techniques but also contributed to driving innovation in the regulated bioanlaysi space. Beyond his work at Pharmaron, Rafiq serves as a scientific advisory board member for the Journal of Biochemistry and Analytical Studies and Somru Bioscience, reflecting his thought leadership in the field. He has authored and contributed to over 50 scientific articles, whitepapers, and posters, influencing the landscape of regulated bioanalysis.